Table 2. Donor KIR profile and CMV reactivation.
| Group I * n=51 |
Group II * n=115 |
Group III * n=45 |
p value | ||
|---|---|---|---|---|---|
| CMV reactivation | |||||
| yes | 44 (86%) | 86 (75%) | 22 (48%) | p<0.001a | |
| no | 7 (14%) | 29 (25%) | 23 (52%) | ||
| CMV episodes | |||||
| none | 13 (25%) | 41 (36%) | 28 (62%) | 0.001b | |
| 1 | 22 (43%) | 43 (37%) | 12 (27%) | ||
| 2 | 10 (20%) | 26 (23%) | 5 (11%) | ||
| 3 | 6 (12%) | 3 (3%) | 0 | ||
| >3 | 0 | 2 (1.6%) | 0 | ||
| CMV Infection: median time to first event in days (range) | |||||
| Q-PCRd | 37 (21-356) | 50 (22-153) | 44 (22-87) | 0.15c | |
| SV assayd | 47 (30-122) | 47 (21-259) | 47 (27-76) | 0.37c | |
| CMV Disease: number (%) | |||||
| CMV pneumonitis | 2 (3.9%) | 3 (2.6%) | 0 | 0.47a | |
| CMV gastroenterocolitis | 4 (7.8%) | 5 (4.3%) | 1(2.2%) | ||
*
Group I: no 2DS2 –no 2DS4; Group II: 2DS2 or 2DS4; Group III: 2DS2 and 2DS4 or ≥ 5aKIR
a
Chi-square test
b
Chi-square test on episodes 0-3
c
Kruskal-Wallis test
d
Q-PCR plasma CMV > 200gc/ml; SV: shell vial assay